MA45280A - Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation - Google Patents

Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Info

Publication number
MA45280A
MA45280A MA045280A MA45280A MA45280A MA 45280 A MA45280 A MA 45280A MA 045280 A MA045280 A MA 045280A MA 45280 A MA45280 A MA 45280A MA 45280 A MA45280 A MA 45280A
Authority
MA
Morocco
Prior art keywords
antibulin
methods
drug conjugates
based drug
conjugates
Prior art date
Application number
MA045280A
Other languages
English (en)
Other versions
MA45280B1 (fr
Inventor
Earl F Albone
Xin Cheng
Daniel W Custar
Keiji Furuuchi
Jing Li
Utpal Majumder
Toshimitsu Uenaka
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA45280A publication Critical patent/MA45280A/fr
Publication of MA45280B1 publication Critical patent/MA45280B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MA45280A 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation MA45280B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302562P 2016-03-02 2016-03-02
PCT/US2017/020529 WO2017151979A1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA45280A true MA45280A (fr) 2019-01-09
MA45280B1 MA45280B1 (fr) 2021-08-31

Family

ID=58347964

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45280A MA45280B1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Country Status (34)

Country Link
US (4) US10548986B2 (fr)
EP (2) EP3423105B1 (fr)
JP (5) JP6599019B2 (fr)
KR (4) KR102445255B1 (fr)
CN (4) CN108883198B (fr)
AR (3) AR107787A1 (fr)
AU (2) AU2017225982B2 (fr)
BR (1) BR112018067379A2 (fr)
CA (1) CA3013791A1 (fr)
CL (3) CL2018002456A1 (fr)
CO (1) CO2018008667A2 (fr)
CY (1) CY1124628T1 (fr)
DK (1) DK3423105T3 (fr)
ES (1) ES2880402T3 (fr)
HR (1) HRP20211125T1 (fr)
HU (1) HUE054726T2 (fr)
IL (2) IL292946A (fr)
JO (3) JOP20170053B1 (fr)
LT (1) LT3423105T (fr)
MA (1) MA45280B1 (fr)
MD (1) MD3423105T2 (fr)
MX (4) MX2018010562A (fr)
MY (1) MY189113A (fr)
PE (3) PE20231050A1 (fr)
PH (1) PH12018501847A1 (fr)
PL (1) PL3423105T3 (fr)
PT (1) PT3423105T (fr)
RS (1) RS62108B1 (fr)
RU (2) RU2021125492A (fr)
SG (2) SG11201806515RA (fr)
SI (1) SI3423105T1 (fr)
TW (2) TWI772288B (fr)
UA (1) UA125024C2 (fr)
WO (1) WO2017151979A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241099B2 (en) * 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2016283343B2 (en) * 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
WO2016208696A1 (fr) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 Protéine hybride contenant un bdnf
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
EP3606928B1 (fr) 2017-04-05 2022-09-07 President and Fellows of Harvard College Composé macrocyclique et utilisations de celui-ci
IL307273A (en) 2017-07-06 2023-11-01 Harvard College Synthesis of the Lichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20230158141A1 (en) 2017-11-08 2023-05-25 Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd Conjugates of Biomolecule and Use Thereof
WO2019099646A1 (fr) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Composés macrocycliques et utilisations de ces composés
CA3099920A1 (fr) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Conjugues anticorps-medicament modulateurs d'epissage et procedes d'utilisation
EP3801523A2 (fr) 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Procédés d'utilisation de modulateurs d'épissage
JP7458981B2 (ja) 2018-08-06 2024-04-01 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2022515760A (ja) * 2018-12-21 2022-02-22 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
CN114729042A (zh) 2019-11-07 2022-07-08 卫材R&D管理有限公司 抗间皮素艾日布林抗体-药物缀合物及使用方法
BR112022012546A2 (pt) 2019-12-23 2022-09-06 Eisai R&D Man Co Ltd Método para produzir conjugado anticorpo-fármaco à base de eribulina
JP2023511163A (ja) * 2020-01-22 2023-03-16 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
KR20220018954A (ko) * 2020-08-07 2022-02-15 주식회사 피노바이오 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
WO2022056278A1 (fr) * 2020-09-11 2022-03-17 Alexion Pharmaceuticals, Inc. Anticorps anti-céruloplasmine et leurs utilisations
CN116390733A (zh) * 2020-09-28 2023-07-04 纳夫罗根公司 用于治疗癌症的替代性格式化的抗间皮素抗体的组合物和用途
WO2022082068A1 (fr) * 2020-10-18 2022-04-21 Ardeagen Corporation Agents de liaison anti-msln, leurs conjugués et leurs procédés d'utilisation
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
JP2024518709A (ja) * 2021-04-10 2024-05-02 プロファウンドバイオ ユーエス カンパニー Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
CN117295524A (zh) * 2021-06-02 2023-12-26 百奥泰生物制药股份有限公司 药物偶联物及其用途
WO2023001300A1 (fr) * 2021-07-22 2023-01-26 上海森辉医药有限公司 Conjugué de médicament de dérivé d'éribuline
WO2023016488A1 (fr) * 2021-08-13 2023-02-16 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament à base d'inhibiteur de microtubules
CN117881431A (zh) * 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
TW202327661A (zh) * 2021-09-16 2023-07-16 大陸商正大天晴藥業集團股份有限公司 抗her3抗體藥物偶聯物及其組合物和用途
WO2023055376A1 (fr) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Anticorps multispécifiques pour cibler cd47 et icam1 et leurs procédés d'utilisation
WO2023061466A1 (fr) * 2021-10-14 2023-04-20 江苏恒瑞医药股份有限公司 Procédé de préparation d'un dérivé d'éribuline
CN116199740A (zh) * 2021-12-01 2023-06-02 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
WO2023103854A1 (fr) * 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament présentant une affinité améliorée, son procédé de préparation et son application
WO2023124963A1 (fr) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament ayant une réaction réversible réduite, procédé de préparation s'y rapportant et application associée
WO2023143319A1 (fr) * 2022-01-28 2023-08-03 启德医药科技（苏州）有限公司 Conjugué anticorps-médicament, composition pharmaceutique et leur utilisation
WO2023143320A1 (fr) * 2022-01-28 2023-08-03 博瑞生物医药（苏州）股份有限公司 Lieur pour la préparation d'un conjugué anticorps-médicament, composé et utilisation
WO2023155808A1 (fr) * 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 Conjugué d'anticorps-éribuline ou un dérivé de celui-ci, intermédiaire de celui-ci, son procédé de préparation, composition pharmaceutique de celui-ci et son utilisation
WO2023170247A1 (fr) 2022-03-11 2023-09-14 Mablink Bioscience Conjugués anticorps-médicament et leurs utilisations
WO2023200814A1 (fr) * 2022-04-12 2023-10-19 Eisai R & D Management Co., Ltd. Conjugués anticorps-médicament à base d'éribuline et procédés d'utilisation
WO2023198079A1 (fr) * 2022-04-12 2023-10-19 百奥泰生物制药股份有限公司 Méthode de traitement d'une tumeur solide positive à her2
WO2024078612A1 (fr) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Composé de charge utile et de lieur, conjugués et applications associées
CN117917248A (zh) * 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
WO1997032572A2 (fr) 1996-03-04 1997-09-12 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6019963A (en) 1998-11-20 2000-02-01 D.S.C. Products, Inc. Deodorizing composition containing tea tree and eucalyptus oils
US7109019B2 (en) 1999-01-06 2006-09-19 The Regents Of The University Of California Gene cluster for production of the enediyne antitumor antibiotic C-1027
CA2445826C (fr) 2001-05-02 2014-03-25 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
EP1545613B9 (fr) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
JP2004119755A (ja) 2002-09-27 2004-04-15 Alps Electric Co Ltd 磁気検出素子及びその製造方法
US20040071540A1 (en) 2002-10-15 2004-04-15 Lucas Philip J. Disposable/recyclable pallet system and method
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP2338333B1 (fr) 2003-04-09 2017-09-06 ratiopharm GmbH Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
CA2538570A1 (fr) 2003-09-18 2005-03-31 Combinatorx, Incorporated Associations de medicaments destinees au traitement de tumeurs
US6997024B2 (en) 2003-10-01 2006-02-14 Truth Hardware Corporation Pull door lock
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US7117807B2 (en) 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
EP1778298A4 (fr) 2004-04-01 2010-03-31 Univ Pennsylvania Nanoplateformes lipoproteiniques
AU2005247346A1 (en) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
JP5226304B2 (ja) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の調製用中間体
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
EP1828776A4 (fr) 2004-12-09 2010-03-17 Eisai R&D Man Co Ltd Criblage d'isotype de tubuline en therapie du cancer, au moyen d'analogues d'hemiasterline
WO2007008603A1 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
GB0515025D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
CA2620362A1 (fr) 2005-09-14 2007-03-22 Ucb Pharma S.A. Polymeres a structure en peigne
CA2632903C (fr) 2005-12-02 2015-11-24 Vianova Labs, Inc. Traitement du cancer et d'autres maladies
WO2007128884A1 (fr) 2006-05-09 2007-11-15 Oy Jurilab Ltd Gènes et marqueurs atypiques dans le diabète de type 2 et l'obésité
US20150030534A1 (en) 2013-07-26 2015-01-29 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US20140037539A1 (en) 2012-07-27 2014-02-06 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (fr) 2007-03-14 2016-09-20 Endocyte, Inc. Conjugues d'administration de medicament lies a un ligand de liaison de tubulysines
EP1977765A1 (fr) 2007-04-03 2008-10-08 Diatos Promédicaments de peptide
CN101883763B (zh) 2007-10-03 2016-04-20 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
WO2009057304A1 (fr) 2007-10-30 2009-05-07 Fujitsu Limited Dispositif de terminal mobile
NO2842575T3 (fr) 2008-03-18 2018-02-24
US8741861B2 (en) 2008-03-27 2014-06-03 Vascular Biosciences Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102083461B (zh) * 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AU2009292437A1 (en) 2008-09-12 2010-03-18 Santen Pharmaceutical Co., Ltd. Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
EP2772269A3 (fr) 2009-03-05 2015-01-14 Abbvie Inc. Protéines se liant à un IL-17
US20140339088A1 (en) 2009-03-09 2014-11-20 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
SG10201402021YA (en) 2009-05-01 2014-10-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8686520B2 (en) * 2009-05-29 2014-04-01 International Business Machines Corporation Spin-torque magnetoresistive structures
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP6088246B2 (ja) * 2009-08-15 2017-03-01 ジェネンテック， インコーポレイテッド 以前に治療された乳癌の治療のための抗血管新生療法
WO2011028811A2 (fr) * 2009-09-01 2011-03-10 Abbott Laboratories Immunoglobulines à double domaine variable et leurs utilisations
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
CN110386876A (zh) 2010-03-24 2019-10-29 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
CN111012921A (zh) 2010-06-15 2020-04-17 根马布股份公司 针对组织因子的人抗体药物缀合物
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
EP2613810B9 (fr) 2010-09-07 2016-02-17 Johannes Kepler Universität Linz Poly(organo)phosphazènes biodégradables, hydrosolubles et répondant au ph
WO2012065019A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs pyridopyrimidinone de p13k alpha
WO2012065057A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
AU2011336396B2 (en) 2010-12-02 2016-02-04 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CA2821976A1 (fr) 2010-12-21 2012-09-13 Abbvie Inc. Immunoglobulines a double domaine variable et leurs utilisations
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (fr) 2010-12-22 2016-05-11 Abbvie Inc Protéines de liaison à une demi-immunoglobuline et leurs utilisations
US20140024539A1 (en) 2011-02-02 2014-01-23 Translational Genomics Research Institute Biomarkers and methods of use thereof
CA2827443C (fr) 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Compositions therapeutiques et procedes d'administration ciblee de molecules bioactives par des minicellules bacteriennes basee sur des molecules de ciblage contenant un fragment fc et des anticorps
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012119077A1 (fr) 2011-03-02 2012-09-07 Morphotek Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
WO2012118978A1 (fr) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Procédés pour traiter des cancers positifs aux oncovirus
EP2681196B1 (fr) 2011-03-04 2015-09-09 Life Technologies Corporation Composés et procédés de conjugaison de biomolécules
CA2830240A1 (fr) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methodes de traitement du cancer du sein par une therapie par anthracycline
JP2014509515A (ja) 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
WO2012145098A1 (fr) 2011-04-21 2012-10-26 Saint Louis University Utilisation d'agonistes du récepteur à l'adénosine a3 pour le traitement de la douleur neuropathique
SG195183A1 (en) 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
KR102030856B1 (ko) 2011-05-27 2019-10-10 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
WO2012170640A1 (fr) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Procédés et compositions pour traitement par une combinaison trail-médicament
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
WO2013078559A1 (fr) 2011-11-30 2013-06-06 Alphora Research Inc. Procédé de préparation de (3r)-2,4-di-groupe partant-3-méthylbut-1-ène
CA2857395A1 (fr) 2011-12-16 2013-06-20 Alphora Research Inc. Procede de preparation de derives de 3-((2s,5s)-4-methylene-5- (3-oxopropyl)tetrahydrofuran-2-yl)propanol et d'intermediaires utiles a leur preparation
EP2794653B1 (fr) 2011-12-23 2019-03-13 Pfizer Inc Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2013092998A1 (fr) 2011-12-23 2013-06-27 Innate Pharma Conjugaison enzymatique d'anticorps
EP2797945B1 (fr) 2011-12-29 2016-03-16 Alphora Research Inc. Dérivés de 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-méthoxy-3-(phénylsulfonylméthyl)tétrahydrofurane-2-yl)acétaldéhyde et procédé pour leur préparation
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013130093A1 (fr) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2013138371A1 (fr) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
KR20150002706A (ko) 2012-03-29 2015-01-07 알토 바이오사이언스 코포레이션 종양 형성 치료방법
EP2831082B1 (fr) 2012-03-30 2019-02-20 Sandoz AG Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans celui-ci
CN104684579A (zh) 2012-04-02 2015-06-03 梅里麦克制药股份有限公司 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
EP2850059A4 (fr) 2012-05-15 2016-06-29 Concortis Biosystems Corp Conjugués de médicament, procédés de conjugaison et utilisation de ceux-ci
IN2014DN09582A (fr) 2012-05-15 2015-07-17 Diatech Oncology Llc
NZ703298A (en) 2012-06-07 2016-04-29 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
WO2013182668A1 (fr) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Sélectivité mutante et associations d'un inhibiteur de phospho‑inositide 3 kinase et agents chimiothérapeutiques pour le traitement du cancer
EP3488870B1 (fr) 2012-06-19 2024-03-20 Ambrx, Inc. Conjugués anticorps-médicament anti-cd70
WO2014005010A2 (fr) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Méthodes de traitement du cancer du sein par une thérapie par la gemcitabine
US9220695B2 (en) 2012-06-29 2015-12-29 The Research Foundation For The State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
PT3210627T (pt) 2012-07-12 2023-03-23 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de ligação celular com agentes citotóxicos
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
US9872919B2 (en) 2012-09-19 2018-01-23 The Research Foundation For The State University Of New York Prodrugs for selective anticancer therapy
SI2903616T1 (en) 2012-10-04 2018-02-28 Ab Science The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
WO2014058317A1 (fr) 2012-10-10 2014-04-17 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Procédés et moyens de prédiction de résistance à un traitement anti-cancer
WO2014063443A1 (fr) 2012-10-22 2014-05-01 Zhang Yuliang Procédé de travail thermique auto-refroidissant
SI2911699T1 (en) 2012-10-23 2018-04-30 Synaffix B.V. MODIFIED AGAINST, PROTITELO-KONJUGAT AND PROCESS FOR THEIR PREPARATION
DK2917195T5 (en) 2012-11-05 2018-08-06 Pfizer SPLICEOSTATINAL ANALOGES
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
AU2013356241A1 (en) 2012-12-03 2015-07-09 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP2934596A1 (fr) 2012-12-21 2015-10-28 Glykos Finland Oy Conjugués constitués de molécules de charge utile et de lieurs
US20150182634A1 (en) 2012-12-28 2015-07-02 Cody P. Coyne Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
CA2898329A1 (fr) 2013-01-19 2014-07-24 New York University Oligooxopiperazines pour la reactivation du p53
US9605026B2 (en) 2013-01-19 2017-03-28 New York University Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
FI3922241T3 (fi) 2013-02-01 2023-11-28 Celator Pharmaceuticals Inc Niukasti liukoisten lääkkeiden etälataus liposomeihin
WO2014121235A2 (fr) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation de compositions de type complexe médicament-cyclodextrine en compositions constituées de mélanges de médicament encapsulé dans des vésicules lipidiques et de complexes cyclodextrine-médicament
WO2014124322A1 (fr) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticules utilisables en vue de l'administration de médicaments
WO2014130776A1 (fr) 2013-02-22 2014-08-28 University Of Houston Phosphaplatines en tant qu'agents neuroprotecteurs
NZ711948A (en) 2013-03-13 2020-02-28 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2015073072A1 (fr) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN110420329A (zh) 2013-03-14 2019-11-08 佛罗里达大学研究基金会 利用天然化合物和/或饮食调控癌症
CN105358174B (zh) 2013-03-15 2019-03-15 酵活有限公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
WO2014168721A2 (fr) 2013-04-12 2014-10-16 Tufts Medical Center Procédés et systèmes pour mettre au point et/ou caractériser des agents ligands lipidés solubles
WO2014176284A1 (fr) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Compositions et procédés d'utilisation pour l'administration sélective de médicaments
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
US20160106860A1 (en) 2013-05-02 2016-04-21 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2014183211A1 (fr) 2013-05-15 2014-11-20 Alphora Research Inc. Dérivés de 3-((2s,5s)-4-méthylène-5-(3-oxopropyl)tétrahydrofuran-2-yl)propanol, leur préparation et intermédiaires utiles correspondants
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
WO2014197871A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Conjugués anticorps-médicament, compositions et méthodes d'utilisation correspondantes
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2014206466A1 (fr) 2013-06-26 2014-12-31 Afg Technologies S.À.R.L Criblage, diagnostic, pronostic et traitement du cancer des ovaires
CA2916537C (fr) 2013-07-03 2021-07-27 Alphora Research Inc. Procede de synthese pour la preparation d'analogues c1-ceto macrocycliques de l'halichondrine b et intermediaires utiles dans la synthese, notamment des intermediaires contenant d es groupes -so2-(p-tolyle)
WO2015017729A1 (fr) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Procédés de diélectrophorèse pour déterminer une propriété d'une pluralité de cellules cancéreuses
US20160166637A1 (en) 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015031541A1 (fr) 2013-08-28 2015-03-05 Stem Centrx, Inc. Nouveaux modulateurs sez6 et procédés d'utilisation
JP2016537010A (ja) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
WO2015038426A1 (fr) 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US20150093331A1 (en) 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US9878049B2 (en) 2013-10-09 2018-01-30 The University Of Akron High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
CA3178299A1 (fr) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps tem8 et leur utilisation
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
EP3054991B1 (fr) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Conjugués de médicament-protéine-polymère
JP6684706B2 (ja) 2013-10-21 2020-04-22 ヘモシアー・リミテッド・ライアビリティ・カンパニーＨｅｍｏＳｈｅａｒ， ＬＬＣ 腫瘍微細環境のための試験管内モデル
BR112016009452B1 (pt) 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
WO2015069266A1 (fr) 2013-11-07 2015-05-14 Flynn Daniel L Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
KR20240006008A (ko) 2013-11-15 2024-01-12 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도
WO2015081282A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
ES2723355T3 (es) 2013-12-06 2019-08-26 Eisai R&D Man Co Ltd Métodos útiles en la síntesis de análogos de halicondrina B
WO2015095784A1 (fr) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Formulation de nanoparticules solides d'inhibiteurs des microtubules à mûrissement d'ostwald réduit pour une administration par voie orale
AU2015205756A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating EGFR expressing tumors
EP3092027A4 (fr) 2014-01-10 2017-09-06 Atossa Genetics Inc. Procédés et compositions transpapillaires pour le dignostic et le traitement de maladies du sein
EP3091970B1 (fr) 2014-01-10 2020-10-28 Rgenix, Inc. Agonistes du récepteur x du foie et leurs utilisations
CN109316605B (zh) 2014-01-20 2023-07-14 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
JP5957637B2 (ja) * 2014-02-03 2016-07-27 国立研究開発法人国立がん研究センター 抗ＴｉｓｓｕｅＦａｃｔｏｒモノクローナル抗体
AU2015212733B2 (en) 2014-02-03 2018-06-07 Eidgenoessische Technische Hochschule Zurich Small molecule drug conjugates
EP2913064A1 (fr) 2014-02-26 2015-09-02 celares GmbH Conjugués de lieurs de médicaments ramifiés pour le couplage à des molécules biologiques de ciblage
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
MX2016011698A (es) 2014-03-13 2016-12-12 Hoffmann La Roche Metodos y composiciones para modular mutantes de receptor de estrogeno.
US9260478B2 (en) * 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
WO2015157471A1 (fr) 2014-04-08 2015-10-15 The Methodist Hospital Compositions inhibitrices d'inos et leur utilisation comme agents thérapeutiques de cancer du sein
CA2945367A1 (fr) 2014-04-14 2015-10-22 Endocyte, Inc. Conjugues pour l'administration de medicaments destines au traitement de cancers resistants et pour une utilisation en therapie combinee
WO2015161247A1 (fr) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Anticorps anti-c16orf54 humanisés et leurs méthodes d'utilisation
WO2015195925A1 (fr) * 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Conjugués médicament-protéine-polymère et leurs procédés d'utilisation
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3069734A1 (fr) * 2015-03-17 2016-09-21 Exiris S.r.l. Conjugués anticorps-médicament à base de cryptophycine avec de nouveaux lieurs auto-immolateurs
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CN107921144B (zh) 2015-06-20 2023-11-28 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物

Also Published As

Publication number Publication date
JOP20170053B1 (ar) 2021-08-17
WO2017151979A1 (fr) 2017-09-08
CN114191428A (zh) 2022-03-18
RU2018134331A (ru) 2020-04-02
JP2021185176A (ja) 2021-12-09
US10322192B2 (en) 2019-06-18
AU2017225982A1 (en) 2018-08-16
KR102445255B1 (ko) 2022-09-22
JP6870051B2 (ja) 2021-05-12
AU2017225982B2 (en) 2023-10-05
PE20181953A1 (es) 2018-12-17
CN114191563A (zh) 2022-03-18
KR20240007722A (ko) 2024-01-16
PE20231049A1 (es) 2023-07-11
SG10202007520WA (en) 2020-09-29
JOP20210073A1 (ar) 2023-01-30
PE20231050A1 (es) 2023-07-11
US20180193478A1 (en) 2018-07-12
IL292946A (en) 2022-07-01
CA3013791A1 (fr) 2017-09-08
MY189113A (en) 2022-01-26
IL261428A (en) 2018-10-31
JP6599019B2 (ja) 2019-10-30
UA125024C2 (uk) 2021-12-29
CN108883198B (zh) 2022-08-09
CN114272389B (zh) 2023-04-18
MD3423105T2 (ro) 2021-10-31
TW201800110A (zh) 2018-01-01
MX2023003809A (es) 2023-04-12
MA45280B1 (fr) 2021-08-31
JP7254861B2 (ja) 2023-04-10
TWI825834B (zh) 2023-12-11
EP3423105A1 (fr) 2019-01-09
RU2021125492A (ru) 2022-04-05
JP2023082096A (ja) 2023-06-13
TWI772288B (zh) 2022-08-01
AR107787A1 (es) 2018-06-06
PT3423105T (pt) 2021-07-19
HRP20211125T1 (hr) 2021-10-15
MX2023003808A (es) 2023-04-12
JP2020019787A (ja) 2020-02-06
CL2021000049A1 (es) 2021-05-28
DK3423105T3 (da) 2021-07-26
US20230398228A1 (en) 2023-12-14
ES2880402T3 (es) 2021-11-24
US20200297860A1 (en) 2020-09-24
EP3824909A1 (fr) 2021-05-26
AR121302A2 (es) 2022-05-04
AU2023285804A1 (en) 2024-01-18
US20170252458A1 (en) 2017-09-07
CL2021000048A1 (es) 2021-05-28
HUE054726T2 (hu) 2021-09-28
KR20220101204A (ko) 2022-07-19
RU2754369C2 (ru) 2021-09-01
KR20220101203A (ko) 2022-07-19
CN108883198A (zh) 2018-11-23
BR112018067379A2 (pt) 2019-01-15
KR102456433B1 (ko) 2022-10-19
AR121301A2 (es) 2022-05-04
JP2019516664A (ja) 2019-06-20
RU2018134331A3 (fr) 2020-08-14
TW202241524A (zh) 2022-11-01
JP2020128413A (ja) 2020-08-27
PH12018501847A1 (en) 2019-05-15
CO2018008667A2 (es) 2018-08-31
PL3423105T3 (pl) 2021-10-25
SG11201806515RA (en) 2018-09-27
LT3423105T (lt) 2021-09-10
EP3423105B1 (fr) 2021-05-05
US10548986B2 (en) 2020-02-04
CY1124628T1 (el) 2022-07-22
KR20180115330A (ko) 2018-10-22
SI3423105T1 (sl) 2021-12-31
CN114272389A (zh) 2022-04-05
CL2018002456A1 (es) 2018-12-21
MX2018010562A (es) 2019-02-20
RS62108B1 (sr) 2021-08-31
JOP20210074A1 (ar) 2023-01-30
MX2023003806A (es) 2023-04-12

Similar Documents

Publication Publication Date Title
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA49520A (fr) Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44490A (fr) Adhésifs biocompatibles et leurs procédés d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation